"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Mice with two fathers have been born—and have survived to adulthood—following a complex set of experiments by a team in China ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Researchers at Beijing's Chinese Academy of Sciences have used the gene-editing technology CRISPR to create mice from two ...

Northwestern Medicine scientists have uncovered new details explaining how poxviruses manipulate host cells to enhance their ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...